AU2015208837B2 - Hybridosomes, compositions comprising the same, processes for their production and uses thereof - Google Patents

Hybridosomes, compositions comprising the same, processes for their production and uses thereof Download PDF

Info

Publication number
AU2015208837B2
AU2015208837B2 AU2015208837A AU2015208837A AU2015208837B2 AU 2015208837 B2 AU2015208837 B2 AU 2015208837B2 AU 2015208837 A AU2015208837 A AU 2015208837A AU 2015208837 A AU2015208837 A AU 2015208837A AU 2015208837 B2 AU2015208837 B2 AU 2015208837B2
Authority
AU
Australia
Prior art keywords
hybridosome
lipid
cell
vesicle
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015208837A
Other languages
English (en)
Other versions
AU2015208837A1 (en
Inventor
Joel DE BEER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Resilience Inc
Original Assignee
National Resilience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Resilience Inc filed Critical National Resilience Inc
Publication of AU2015208837A1 publication Critical patent/AU2015208837A1/en
Application granted granted Critical
Publication of AU2015208837B2 publication Critical patent/AU2015208837B2/en
Priority to AU2020227129A priority Critical patent/AU2020227129B2/en
Priority to AU2022218603A priority patent/AU2022218603B2/en
Assigned to NATIONAL RESILIENCE, LLC reassignment NATIONAL RESILIENCE, LLC Request for Assignment Assignors: ANJARIUM BIOSCIENCES AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AU2015208837A 2014-01-21 2015-01-20 Hybridosomes, compositions comprising the same, processes for their production and uses thereof Active AU2015208837B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020227129A AU2020227129B2 (en) 2014-01-21 2020-09-07 Hybridosomes, compositions comprising the same, processes for their production and uses thereof
AU2022218603A AU2022218603B2 (en) 2014-01-21 2022-08-19 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461929559P 2014-01-21 2014-01-21
US61/929,559 2014-01-21
PCT/IB2015/050436 WO2015110957A2 (en) 2014-01-21 2015-01-20 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020227129A Division AU2020227129B2 (en) 2014-01-21 2020-09-07 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Publications (2)

Publication Number Publication Date
AU2015208837A1 AU2015208837A1 (en) 2016-08-11
AU2015208837B2 true AU2015208837B2 (en) 2020-06-18

Family

ID=52434912

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015208837A Active AU2015208837B2 (en) 2014-01-21 2015-01-20 Hybridosomes, compositions comprising the same, processes for their production and uses thereof
AU2020227129A Active AU2020227129B2 (en) 2014-01-21 2020-09-07 Hybridosomes, compositions comprising the same, processes for their production and uses thereof
AU2022218603A Active AU2022218603B2 (en) 2014-01-21 2022-08-19 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020227129A Active AU2020227129B2 (en) 2014-01-21 2020-09-07 Hybridosomes, compositions comprising the same, processes for their production and uses thereof
AU2022218603A Active AU2022218603B2 (en) 2014-01-21 2022-08-19 Hybridosomes, compositions comprising the same, processes for their production and uses thereof

Country Status (13)

Country Link
US (3) US10561610B2 (enExample)
EP (2) EP3791863B1 (enExample)
JP (3) JP6598786B2 (enExample)
KR (3) KR102396026B1 (enExample)
CN (2) CN112870163A (enExample)
AU (3) AU2015208837B2 (enExample)
CA (1) CA2936514C (enExample)
DK (1) DK3096741T3 (enExample)
EA (1) EA037503B1 (enExample)
ES (1) ES2821758T3 (enExample)
MX (2) MX384911B (enExample)
WO (1) WO2015110957A2 (enExample)
ZA (1) ZA201604831B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
WO2014210448A1 (en) 2013-06-27 2014-12-31 The Board Of Regents Of The University Of Texas System Compositions and methods relating to myomaker-induced muscle cell fusion
EA037503B1 (ru) 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
WO2015157652A1 (en) 2014-04-11 2015-10-15 University Of Louisville Research Foundation, Inc. Coated edible plant-derived microvesicle compositions and methods for using the same
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2017136430A1 (en) 2016-02-01 2017-08-10 The Board Of Trustees Of The Leland Stanford Junior University Exosome-total-isoloation-chip (exotic) device for isolation of exosome-based biomarkers
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
CN115837014A (zh) * 2016-05-18 2023-03-24 摩登纳特斯有限公司 编码松弛素的多核苷酸
CN106280533B (zh) * 2016-08-17 2018-03-09 赣南师范大学 一种近红外荧光染料及其合成方法和用于寄生虫荧光标记
EP3292861A1 (en) * 2016-09-13 2018-03-14 Centre National De La Recherche Scientifique (Cnrs) An in vitro method for obtaining a biohybrid vector
BR112019022016A2 (pt) * 2017-04-19 2020-05-12 Apa- Advanced Technologies Ltd. Lipossomas fusogênicos, composições, kits e uso dos mesmos no tratamento do câncer
CN107084956B (zh) * 2017-05-05 2021-03-23 曲阜师范大学 一种基于醇溶剂诱导银纳米簇荧光增强的尿液中碘离子检测方法
US11576872B2 (en) * 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP3658125A4 (en) * 2017-07-28 2021-04-28 National University of Singapore BIOMOLECULAR COMPOSITES INCLUDING MODIFIED CELL PHANTOMS
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
CN111225975A (zh) * 2017-09-11 2020-06-02 加利福尼亚大学董事会 抗体介导的cas9向哺乳动物细胞的递送
WO2019066434A1 (ko) * 2017-09-30 2019-04-04 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
KR102008665B1 (ko) * 2017-09-30 2019-08-08 주식회사 엑소코바이오 사포게닌과 엑소좀을 유효성분으로 포함하는 조성물
US20200330616A1 (en) * 2017-11-13 2020-10-22 POLITECNICO Dl TORINO Biomimetic non-immunogenic nanoassembly for the antitumor therapy
US12036262B2 (en) 2017-11-22 2024-07-16 University Of Louisville Research Foundation, Inc. Edible plant-derived nanoparticles for regulation of gut microbiota
CN108287134B (zh) * 2017-12-28 2020-11-24 南京邮电大学 单颗粒生物探针及其等离子体生物存储器的构建方法
BR112020016570A2 (pt) 2018-02-17 2020-12-15 Flagship Pioneering Innovations V, Inc. Composições e métodos para liberação de proteína de membrana
US12241888B2 (en) 2018-03-14 2025-03-04 Children's Medical Center Corporation Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof
CN112135639B (zh) 2018-04-06 2023-10-20 北卡罗莱纳州立大学 细胞组装介导的癌症免疫治疗检查点抑制剂的递送
KR20200141080A (ko) 2018-04-09 2020-12-17 오르제네시스 인코포레이티드 바이옥솜 입자, 레독솜, 방법 및 조성물
EP3784220A4 (en) * 2018-04-26 2022-05-11 University Of Louisville Research Foundation, Inc. EXOSOME-LIKE NANOVECTORS FROM EDIBLE PLANT FOR VACCINE
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN110437628B (zh) * 2018-05-04 2021-05-04 中国石油化工股份有限公司 一种改性剂母液和道路沥青及其合成方法
CN112367973A (zh) * 2018-05-15 2021-02-12 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN112543629A (zh) * 2018-06-28 2021-03-23 阿斯利康(瑞典)有限公司 外泌体胞外囊泡及其使用方法
CA3105953A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
WO2020084623A2 (en) * 2018-10-24 2020-04-30 Apa- Advanced Technologies Ltd. Fusogenic liposomes for selective imaging of tumor cells
US20230048166A1 (en) * 2018-11-14 2023-02-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
KR20210131991A (ko) 2018-11-14 2021-11-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 구획-특이적 카고 전달을 위한 조성물 및 방법
CN109620969B (zh) * 2019-01-30 2021-02-05 广东药科大学 一种针对耐药肿瘤细胞的靶向抗肿瘤药物体系及其构建方法
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2021010586A1 (ko) * 2019-07-15 2021-01-21 (주)심플스틱 항노화를 위한 피부 리프팅용 화장료 조성물 및 이를 이용한 피부미용 방법
KR20220044816A (ko) * 2019-08-12 2022-04-11 인티그레이티드 나노테라퓨틱스 아이엔씨. 하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
CA3150734A1 (en) * 2019-08-16 2021-02-25 Children's Medical Center Corporation Large scale production of exosome mimetics and uses thereof
CN112415081A (zh) * 2019-08-23 2021-02-26 四川大学 一种基于稳定同位素检测的无标记CRISPR-Cas9分析方法
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
KR102297995B1 (ko) * 2019-10-24 2021-09-02 포항공과대학교 산학협력단 개방 동공을 갖는 산화철 나노큐브, 이의 제조방법 및 이의 용도
CN111007170B (zh) * 2019-12-13 2021-06-29 中国农业科学院农产品加工研究所 骨肽干预治疗骨质疏松中的生物标志物、筛选方法及用途
JP7497850B2 (ja) 2019-12-23 2024-06-11 株式会社アイ・ティー・オー 細胞送達用キャリア
US20230285297A1 (en) * 2020-01-31 2023-09-14 Modernatx, Inc. Methods of preparing lipid nanoparticles
EP3858332A1 (en) * 2020-01-31 2021-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bottom-up assembly of synthetic extracellular vesicles
CN115427021A (zh) * 2020-02-25 2022-12-02 翻译生物公司 制备负载mrna的脂质纳米颗粒的改进方法
US20230143984A1 (en) * 2020-03-20 2023-05-11 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
CN112094809A (zh) * 2020-10-19 2020-12-18 军事科学院军事医学研究院环境医学与作业医学研究所 一种从血清或血浆中提取外泌体的方法
MX2023011243A (es) * 2021-03-23 2023-12-14 Recode Therapeutics Inc Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
JP2024532963A (ja) 2021-04-08 2024-09-11 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８特異的抗体コンストラクト及びその組成物
EP4323396A1 (en) 2021-04-14 2024-02-21 Anjarium Biosciences AG Fc-derived polypeptides
WO2022219075A2 (en) 2021-04-14 2022-10-20 Anjarium Biosciences Ag Peptides, nanovesicles, and uses thereof for drug delivery
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
KR102958597B1 (ko) 2021-06-04 2026-05-04 기초과학연구원 나노소포체 반응기 및 이의 제조방법
CN117460818A (zh) * 2021-06-04 2024-01-26 基础科学研究院 纳米囊泡反应器及其制备方法
WO2022255851A1 (ko) * 2021-06-04 2022-12-08 기초과학연구원 나노소포체 반응기 및 이의 제조방법
CA3226019A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023027082A1 (ja) * 2021-08-23 2023-03-02 積水化学工業株式会社 ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023244084A1 (ko) * 2022-06-17 2023-12-21 주식회사 엠디뮨 양이온성 지질 및 핵산분자를 포함하는 세포유래 베지클 및 이의 제조방법
JP2025535944A (ja) 2022-10-24 2025-10-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、鼻腔内投与時のそれらの生体内分布、及びそれらの使用
WO2024170778A1 (en) 2023-02-17 2024-08-22 Anjarium Biosciences Ag Methods of making dna molecules and compositions and uses thereof
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma
WO2024249782A2 (en) * 2023-06-02 2024-12-05 The Methodist Hospital Biomimetic proteolipid nanovesicles for delivery of nucleic acids
EP4719632A1 (en) 2023-07-06 2026-04-08 National Resilience, LLC Methods and compositions for purifying particles and macromolecules
KR20250018222A (ko) * 2023-07-26 2025-02-05 차의과학대학교 산학협력단 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물
WO2025100747A1 (ko) * 2023-11-09 2025-05-15 주식회사 엑토좀 줄기세포 유래 엑토-리포좀 융합 나노입자 및 그의 용도
WO2025137252A1 (en) * 2023-12-20 2025-06-26 Cz Biohub Sf, Llc High throughput method for screening lipid nanoparticle efficacy and cytotoxicity
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2025196641A1 (ru) * 2024-03-19 2025-09-25 Биоплатформ Гмбх Гибридные частицы, способ их получения и применение
KR20250150723A (ko) * 2024-04-11 2025-10-21 주식회사 하이셀텍 하이브리드 엑소좀 및 이의 용도
KR20250156281A (ko) * 2024-04-25 2025-11-03 주식회사 보름바이오 고분자 나노입자와 세포막이 하이브리드화된 나노복합체 및 이의 의학적 용도
WO2026141629A1 (ja) * 2024-12-27 2026-07-02 日東電工株式会社 脂質ナノ粒子

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2011097480A1 (en) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
US20110251156A1 (en) * 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
US20130053426A1 (en) * 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
WO2013048734A1 (en) * 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes
US20130195765A1 (en) * 2010-01-07 2013-08-01 Postech Academy-Industry Foundation Method for treating and diagnosing cancer by using cell-derived microvesicles

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552155A (en) * 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
EP1519714B1 (en) * 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010080724A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
KR100950713B1 (ko) 2009-07-15 2010-03-31 (주)블루앤 음이온 발생기를 구비한 엘이디 램프
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
US20120253032A1 (en) 2009-10-08 2012-10-04 Merck Sharp & Dohme Corporation Novel cationic lipids with short lipid chains for oligonucleotide delivery
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
JP5149921B2 (ja) * 2010-02-19 2013-02-20 学校法人君が淵学園 癌細胞増殖抑制性ハイブリッド型リポソーム製剤
WO2011149733A2 (en) 2010-05-24 2011-12-01 Merck Sharp & Dohme Corp. Novel amino alcohol cationic lipids for oligonucleotide delivery
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
KR101130137B1 (ko) 2010-07-02 2012-03-28 연세대학교 산학협력단 발광다이오드 모듈
WO2012024621A2 (en) 2010-08-20 2012-02-23 Selecta Biosciences, Inc. Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
ES2987915T3 (es) 2010-09-20 2024-11-18 Sirna Therapeutics Inc Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
WO2012054365A2 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
DK2635265T3 (en) 2010-11-05 2018-07-16 Sirna Therapeutics Inc New low molecular weight cyclic amine-containing cationic lipids for oligonucleotide delivery
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
US20140308304A1 (en) * 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
JP2013128452A (ja) * 2011-12-21 2013-07-04 Toshiba Corp 定量分析装置、定量分析方法、脂質膜小胞、及び試薬
AU2013355258A1 (en) 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
BR112015018877A2 (pt) 2013-02-07 2017-08-22 Externautics Spa Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
EA037503B1 (ru) 2014-01-21 2021-04-05 Анджариум Байосайенсиз Аг Способ получения гибридосомы, гибридосома, полученная при помощи способа, и способ доставки терапевтического или диагностического средства
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
WO2022219075A2 (en) 2021-04-14 2022-10-20 Anjarium Biosciences Ag Peptides, nanovesicles, and uses thereof for drug delivery
EP4323396A1 (en) 2021-04-14 2024-02-21 Anjarium Biosciences AG Fc-derived polypeptides
JP2024517427A (ja) 2021-04-20 2024-04-22 アンジャリウム バイオサイエンシズ エージー アミロ－α－１，６－グルコシダーゼ、４－α－グルカノトランスフェラーゼをコードするＤＮＡ分子の組成物、その作製の方法、及びその使用の方法
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092153A2 (en) * 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
US20130053426A1 (en) * 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
US20130195765A1 (en) * 2010-01-07 2013-08-01 Postech Academy-Industry Foundation Method for treating and diagnosing cancer by using cell-derived microvesicles
WO2011097480A1 (en) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
US20110251156A1 (en) * 2010-04-07 2011-10-13 Yue Shen Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
WO2013048734A1 (en) * 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARLO A PALMERINI ET AL, "Role of Cholesterol, DOTAP, and DPPC in Prostasome/Spermatozoa Interaction and Fusion", JOURNAL OF MEMBRANE BIOLOGY, SPRINGER-VERLAG, NE, (2006-11-07), vol. 211, no. 3, pages 185 - 190 *
DE LA PENA H ET AL, "Artificial exosomes as tools for basic and clinical immunology", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 344, no. 2, pages 121 - 132, (2009-04-01) *
K. YUYAMA ET AL, "Sphingolipid-modulated Exosome Secretion Promotes Clearance of Amyloid- by Microglia", JOURNAL OF BIOLOGICAL CHEMISTRY, (2012-03-30), vol. 287, no. 14, doi:10.1074/jbc.M111.324616, ISSN 0021-9258, pages 10977 - 10989 *
ROOPA HEBBANDI NANJUNDAPPA ET AL, "Novel CD8T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice", VACCINE, vol. 30, no. 24, (2012-03-25), pages 3519 - 3525 *
SHUBHADEEP BANERJEE ET AL, "Poly(styrene-co-maleic acid)-based pH-sensitive liposomes mediate cytosolic delivery of drugs for enhanced cancer chemotherapy", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (2012-10-01), vol. 436, no. 1-2 p 786 - 797 *

Also Published As

Publication number Publication date
KR102396026B1 (ko) 2022-05-09
US11944706B2 (en) 2024-04-02
EA037503B1 (ru) 2021-04-05
CN105934240A (zh) 2016-09-07
CA2936514A1 (en) 2015-07-30
JP6598786B2 (ja) 2019-10-30
JP2019218349A (ja) 2019-12-26
EA201691448A1 (ru) 2016-12-30
JP2022101548A (ja) 2022-07-06
AU2020227129B2 (en) 2022-06-30
KR102541164B1 (ko) 2023-06-08
MX384911B (es) 2025-03-14
AU2022218603A1 (en) 2022-09-15
MX2021000174A (es) 2021-03-25
EP3791863B1 (en) 2025-09-10
EP3096741B1 (en) 2020-09-02
AU2015208837A1 (en) 2016-08-11
KR20230039752A (ko) 2023-03-21
AU2022218603B2 (en) 2024-10-03
US11484500B2 (en) 2022-11-01
JP2017502997A (ja) 2017-01-26
JP7046872B2 (ja) 2022-04-04
MX2016009529A (es) 2016-10-17
EP3791863A1 (en) 2021-03-17
KR20220061286A (ko) 2022-05-12
US10561610B2 (en) 2020-02-18
ZA201604831B (en) 2018-05-30
US20200222324A1 (en) 2020-07-16
AU2020227129A1 (en) 2020-10-01
CA2936514C (en) 2023-08-08
KR20160110410A (ko) 2016-09-21
CN112870163A (zh) 2021-06-01
ES2821758T3 (es) 2021-04-27
EP3096741A2 (en) 2016-11-30
US20230181467A1 (en) 2023-06-15
KR102507475B1 (ko) 2023-03-07
WO2015110957A2 (en) 2015-07-30
WO2015110957A3 (en) 2015-12-03
DK3096741T3 (da) 2020-09-28
CN105934240B (zh) 2021-02-09
US20160354313A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
US11944706B2 (en) Hybridosomes, compositions comprising the same, processes for their production and uses thereof
Lila et al. Liposomal delivery systems: design optimization and current applications
Jiang et al. Furin-mediated sequential delivery of anticancer cytokine and small-molecule drug shuttled by graphene
CN106619515A (zh) 脂质体组合物及其用途
Chen et al. Sequentially Site‐Specific Delivery of Apoptotic Protein and Tumor‐Suppressor Gene for Combination Cancer Therapy
JP2017512840A (ja) 癌治療のためのターゲティングされた重合ナノ粒子
US20140199233A1 (en) Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
US20210369860A1 (en) Functionalized nanoparticle formulations for oral drug delivery
US20250177301A1 (en) Triplex nanoparticles
Tiefenboeck et al. Microinjection for the ex vivo modification of cells with artificial organelles
WO2014030601A1 (ja) アニオン性を有する新規ナノバブルポリ－リポ・プレックスの製造方法
US20150017098A1 (en) Carrier that targets fucosylated molecule-producing cells
Ou et al. Nano-biohybrid systems for the targeted delivery of chemotherapeutics
BR112016016802B1 (pt) Processo para fabricar um carreador biocompatível híbrido (hibridossoma)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NATIONAL RESILIENCE, LLC

Free format text: FORMER OWNER(S): ANJARIUM BIOSCIENCES AG